Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP | P16233 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | PARG | Q86W56 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020001 | 0.88 | PARP10 (0.33) | PARP10PARP15PARP14LMNASCN3A | |
| SCHEMBL4024269 | 0.77 | LMNA (0.42) | PNLIPLMNAHTTOPRK1OPRM1 | |
| SCHEMBL4020004 | 0.69 | FYN (0.42) | PARP10PARP15PARP14LMNAHTT | |
| SCHEMBL4019651 | 0.67 | PARP10 (0.40) | PARP10PARP15LMNAHTTOPRK1 | |
| SCHEMBL2988681 | 0.67 | PARP10 (0.37) | PARP10LMNAOPRK1OPRM1OPRD1 | |
| SCHEMBL2707659 | 0.66 | CTNNB1 (0.59) | LMNAHTTCTNNB1 | |
| SCHEMBL4017274 | 0.65 | PPARD (0.39) | PARP10PARP15LMNAHTTOPRK1 | |
| SCHEMBL4024256 | 0.65 | DRD4 (0.46) | LMNAHTTOPRK1OPRM1OPRD1 | |
| SCHEMBL4017097 | 0.65 | PPARD (0.42) | LMNAHTT | |
| SCHEMBL4014189 | 0.64 | ROCK2 (0.40) | PARP10PARP15LMNAHTTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618996-B2 | Diaryl ether derivatives and uses thereof | PFIZER INC. (US) | 2009-11-17 | — | — | US | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | PNLIP 1763/4885PARP10 2285/4885PARP15 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.